Arvinas, Inc.

In a year that has so far been marked by major changes and upheaval at the US Food and Drug Administration, pharma companies are largely still on track with their expected 2025 approvals and launches.

The CEO of Arvinas has admitted that Pfizer could seek to renegotiate or even walk away from their partnership to market vepdegestrant, just as the companies submit the protein degrader breast cancer

Unity Biotechnology, a biotech firm developing drugs that eliminate or modulate senescent cells to treat diseases of aging, has been making the case for its approach in retinal diseases for the last f

Hopes that Arvinas/Pfizer’s estrogen receptor-targeting protein degrader vepdegestrant will show improved efficacy in breast cancer over selective estrogen receptor degraders (SERDs) appear dimmer fol